Ciprofloxacin Navamedic

What Is Ciprofloxacin Navamedic and What Is It Used For?

Quick Answer: Ciprofloxacin Navamedic is an intravenous fluoroquinolone antibiotic used to treat serious bacterial infections, including lower respiratory tract infections, complicated urinary tract infections, abdominal infections, bone and joint infections, and severe skin infections. It is reserved for situations where oral therapy is not appropriate or when the severity of infection demands intravenous treatment.

Ciprofloxacin Navamedic belongs to the fluoroquinolone class of antibiotics, one of the most widely prescribed antibiotic groups worldwide. The active substance, ciprofloxacin, exerts its bactericidal effect by inhibiting two critical bacterial enzymes: DNA gyrase (topoisomerase II) and topoisomerase IV. These enzymes are essential for bacterial DNA replication, transcription, repair, and recombination. By blocking these processes, ciprofloxacin causes rapid bacterial cell death. Importantly, ciprofloxacin acts selectively on specific bacterial strains and does not affect all bacteria equally.

This medication is formulated as a solution for intravenous infusion at a concentration of 2 mg/ml. The intravenous route is chosen when patients cannot take oral medications, when the infection is so severe that immediate high drug levels in the bloodstream are required, or when absorption from the gastrointestinal tract may be compromised. Once the clinical situation improves, healthcare providers may switch patients from intravenous to oral ciprofloxacin to continue treatment.

Indications in Adults

In adult patients, Ciprofloxacin Navamedic is prescribed for a range of serious bacterial infections. These include lower respiratory tract infections such as community-acquired pneumonia and hospital-acquired pneumonia, particularly in cases caused by Gram-negative pathogens. It is also used for chronic or recurrent ear and sinus infections that have not responded to other antibiotic treatments. Complicated urinary tract infections, including pyelonephritis (kidney infections), represent one of the most common indications for ciprofloxacin use.

Additionally, ciprofloxacin is used to treat genital tract infections in both women and men, gastrointestinal infections and intra-abdominal infections, skin and soft tissue infections, and bone and joint infections including osteomyelitis. It plays a critical role in treating infections in immunocompromised patients, particularly those with very low white blood cell counts (neutropenia) following chemotherapy. The drug is also used for post-exposure prophylaxis and treatment of inhalational anthrax.

For patients with particularly severe infections or those caused by multiple bacterial species (polymicrobial infections), ciprofloxacin may be combined with other antibiotics to broaden the spectrum of coverage and improve treatment outcomes.

Indications in Children and Adolescents

The use of ciprofloxacin in children and adolescents is more restricted and must be supervised by a specialist physician. It is approved for treating lung and bronchial infections in children and adolescents with cystic fibrosis, a genetic condition that makes these patients highly susceptible to certain bacterial infections, particularly Pseudomonas aeruginosa. Ciprofloxacin is also indicated for complicated urinary tract infections in pediatric patients, including pyelonephritis.

As with adults, ciprofloxacin can be used in children for post-exposure prophylaxis and treatment of inhalational anthrax. In other particularly serious infections where the treating physician determines that the benefits outweigh the risks, ciprofloxacin may be considered. However, due to concerns about potential effects on developing cartilage and joints in growing children, its use in the pediatric population is carefully weighed and typically reserved for situations where alternative antibiotics are not effective.

What Should You Know Before Taking Ciprofloxacin Navamedic?

Quick Answer: Do not use Ciprofloxacin Navamedic if you are allergic to ciprofloxacin or any fluoroquinolone, or if you are taking tizanidine. Tell your doctor about any history of tendon problems, epilepsy, kidney disease, myasthenia gravis, heart conditions, or aortic aneurysm. This medication should be avoided during pregnancy and breastfeeding.

Contraindications

Ciprofloxacin Navamedic must not be used in the following circumstances. Patients with a known allergy (hypersensitivity) to ciprofloxacin, any other fluoroquinolone antibiotic, or any of the excipients in the formulation must not receive this medication. Even a mild previous allergic reaction to a fluoroquinolone should be taken seriously, as subsequent exposures can cause more severe reactions.

The concurrent use of ciprofloxacin with tizanidine is absolutely contraindicated. Tizanidine is a muscle relaxant used for conditions such as multiple sclerosis-related spasticity. When administered together, ciprofloxacin dramatically increases tizanidine blood levels, leading to potentially dangerous hypotension (low blood pressure) and excessive sedation. This interaction is clinically significant and can be life-threatening.

Warnings and Precautions

Before starting treatment with Ciprofloxacin Navamedic, it is essential to inform your healthcare provider about your complete medical history. Several conditions require special caution or dose adjustments when using this medication.

Tendon damage: Fluoroquinolones, including ciprofloxacin, are associated with an increased risk of tendinitis and tendon rupture, particularly the Achilles tendon. This risk is elevated in patients over 60 years of age, organ transplant recipients, patients with kidney problems, and those concurrently receiving corticosteroids. Tendon inflammation and rupture can occur within the first 48 hours of treatment or even months after completing the course. At the first sign of pain, swelling, or inflammation in a tendon, treatment must be discontinued immediately, the affected limb rested, and medical attention sought.

Neurological effects: Patients with epilepsy or other neurological conditions such as reduced cerebral blood flow or history of stroke are at increased risk of central nervous system side effects. These can include seizures, confusion, dizziness, tremor, and hallucinations. Ciprofloxacin should be used with extreme caution in these patients.

Peripheral neuropathy: Symptoms of nerve damage including pain, burning sensations, tingling, numbness, or weakness, particularly in the feet, legs, hands, or arms, have been reported. If these symptoms develop, treatment should be stopped immediately to prevent a potentially irreversible condition.

Psychiatric reactions: Depression, psychosis, and suicidal ideation or attempts have been reported, sometimes after the first dose. Patients experiencing psychiatric symptoms should seek immediate medical attention.

Cardiovascular risks: Caution is required in patients with or at risk of QT interval prolongation, including those with congenital long QT syndrome, electrolyte imbalances (particularly low potassium or magnesium), bradycardia, heart failure, or those taking other QT-prolonging medications. Cases of aortic aneurysm, aortic dissection, and heart valve regurgitation have been reported with fluoroquinolone use.

Blood sugar disturbances: Ciprofloxacin can cause both hyperglycemia and hypoglycemia. Patients with diabetes require careful blood sugar monitoring throughout treatment. Severe hypoglycemia can result in loss of consciousness (hypoglycemic coma).

Kidney disease: Patients with impaired kidney function may require dose adjustments. Adequate fluid intake should be maintained during treatment to prevent crystalluria (crystal formation in urine).

Myasthenia gravis: Ciprofloxacin may worsen muscle weakness in patients with myasthenia gravis and should be used with great caution in these individuals.

Photosensitivity: The skin becomes more sensitive to sunlight and ultraviolet (UV) light during treatment. Patients should avoid exposure to strong sunlight and artificial UV sources such as tanning beds.

Clostridioides difficile-associated diarrhea: Severe diarrhea during or after antibiotic treatment may indicate a potentially life-threatening intestinal infection. If severe or bloody diarrhea develops, treatment should be stopped and medical attention sought immediately. Anti-motility drugs should not be taken in this situation.

Pregnancy and Breastfeeding

Ciprofloxacin should be avoided during pregnancy. Animal studies have shown potential risks to developing cartilage and joints, and although human data are limited, the precautionary principle applies. Safer antibiotic alternatives with established safety profiles during pregnancy should be used whenever possible. If you are pregnant, suspect pregnancy, or are planning to become pregnant, discuss treatment options with your healthcare provider before receiving this medication.

Ciprofloxacin is excreted in breast milk and may be harmful to the nursing infant. Therefore, it must not be used during breastfeeding. If ciprofloxacin treatment is deemed essential, breastfeeding should be temporarily discontinued and appropriate alternatives for infant nutrition should be considered.

Driving and Operating Machinery

Ciprofloxacin can impair alertness and cause neurological side effects including dizziness, visual disturbances, and drowsiness. Patients should not drive or operate machinery until they know how the medication affects them. This is particularly important during the initial days of treatment when the risk of neurological effects may be highest.

How Does Ciprofloxacin Navamedic Interact with Other Drugs?

Quick Answer: Ciprofloxacin has numerous clinically significant drug interactions. The combination with tizanidine is absolutely contraindicated. It increases the blood levels and effects of warfarin, theophylline, methotrexate, caffeine, duloxetine, sildenafil, clozapine, and many other drugs. Always inform your healthcare provider about all medications, supplements, and herbal products you are taking.

Drug interactions with ciprofloxacin are a major clinical concern because this antibiotic inhibits several cytochrome P450 enzymes, particularly CYP1A2, which is involved in the metabolism of many commonly prescribed medications. By inhibiting these enzymes, ciprofloxacin can significantly increase the blood levels and pharmacological effects of other drugs, leading to an enhanced risk of adverse effects and toxicity.

Contraindicated Combination

The combination of ciprofloxacin with tizanidine is absolutely contraindicated and must never occur. Studies have shown that concurrent administration can increase tizanidine plasma levels by up to 10-fold, resulting in severe hypotension and profound sedation. This interaction is due to ciprofloxacin's potent inhibition of CYP1A2, the primary enzyme responsible for tizanidine metabolism.

Major Interactions

Other Notable Interactions

Ciprofloxacin can increase the blood levels and effects of several other medications. These include pentoxifylline (used for circulatory disorders), caffeine (reduced clearance leading to increased CNS stimulatory effects), duloxetine (used for depression and neuropathic pain), lidocaine (local anesthetic and antiarrhythmic), sildenafil (used for erectile dysfunction and pulmonary hypertension), agomelatine (antidepressant), and zolpidem (sleep medication).

Probenecid, a drug used for gout, interferes with the renal excretion of ciprofloxacin, leading to higher ciprofloxacin blood levels. Metoclopramide accelerates the absorption of oral ciprofloxacin, resulting in faster peak blood levels. Omeprazole, a proton pump inhibitor used for stomach ulcers, may slightly reduce ciprofloxacin absorption when taken orally but does not significantly affect intravenous administration.

It is essential to inform your healthcare provider about all medications you are currently taking, including over-the-counter drugs, herbal supplements, and vitamins, to minimize the risk of potentially harmful drug interactions.

What Is the Correct Dosage of Ciprofloxacin Navamedic?

Quick Answer: Ciprofloxacin Navamedic is given as an intravenous infusion of 200–400 mg two to three times daily. A 400 mg dose is infused over 60 minutes and a 200 mg dose over 30 minutes. Treatment typically lasts 5–21 days depending on the infection type and severity. Dose reduction is required in patients with impaired kidney function.

Dosing of Ciprofloxacin Navamedic must always follow the prescribing healthcare provider's instructions. The exact dose, frequency, and duration of treatment depend on the type and severity of the infection, the causative pathogen's susceptibility profile, the patient's renal function, and other individual clinical factors.

Adults

The infusion duration is critically important for minimizing adverse effects. A 400 mg dose must be infused over 60 minutes, while a 200 mg dose should be infused over 30 minutes. Slow infusion into a large vein significantly reduces the patient's discomfort and the risk of venous irritation at the infusion site.

Children and Adolescents

For pediatric patients, the dose is calculated based on body weight and the specific indication. Treatment with ciprofloxacin in children should be initiated and supervised by a physician experienced in treating cystic fibrosis or severe infections in the pediatric population. In children, the infusion must always be administered over 60 minutes regardless of the dose. The standard dose for cystic fibrosis-related lung infections is 10 mg/kg body weight three times daily (maximum 400 mg per dose). For complicated urinary tract infections and pyelonephritis, 6–10 mg/kg body weight three times daily is recommended.

Patients with Kidney Impairment

Ciprofloxacin is partially excreted through the kidneys, and dose adjustments are necessary in patients with reduced renal function. Your healthcare provider will calculate the appropriate dose based on your creatinine clearance. Patients on hemodialysis may require supplemental dosing after dialysis sessions. Adequate fluid intake throughout treatment helps maintain proper renal function and prevents crystal formation in the urinary tract.

Patients with Liver Impairment

No dose adjustment is required for patients with hepatic (liver) impairment alone. However, patients should be monitored for signs of liver toxicity during treatment, including loss of appetite, jaundice (yellowing of the skin or eyes), dark urine, itching, or abdominal tenderness.

Completing the Full Course

What Are the Side Effects of Ciprofloxacin Navamedic?

Quick Answer: Common side effects include nausea, diarrhea, vomiting, injection site reactions, and rash. Serious but less common effects include tendon rupture, peripheral neuropathy, central nervous system effects (seizures, psychosis), aortic aneurysm, and severe allergic reactions. Some effects may be long-lasting, disabling, or permanent.

Like all medications, Ciprofloxacin Navamedic can cause side effects, although not everyone experiences them. The side effects range from mild and transient to severe and potentially life-threatening. Understanding the frequency and nature of these effects helps patients and healthcare providers make informed decisions about treatment.

Long-term and Potentially Irreversible Effects

In very rare cases, fluoroquinolone antibiotics including ciprofloxacin have been associated with long-lasting (months to years), disabling, and potentially permanent adverse effects. These include tendon inflammation and rupture, joint pain, limb pain and difficulty walking, abnormal sensations such as tingling, burning, or numbness (neuropathy), fatigue, sleep disturbances, memory impairment, impaired vision, taste, smell, and hearing, as well as mental health effects including depression, anxiety, and suicidal thoughts.

These effects have been reported regardless of pre-existing risk factors and may occur after only a short course of treatment. Regulatory agencies including the FDA (United States), EMA (European Union), and MHRA (United Kingdom) have issued safety warnings and required updated labeling for all fluoroquinolone antibiotics. If you experience any of these symptoms, contact your healthcare provider immediately before continuing treatment.

Cardiovascular Effects

Cases of aortic aneurysm, aortic dissection (tearing of the aortic wall), and heart valve regurgitation have been reported in patients treated with fluoroquinolones. The risk appears to be elevated in patients concurrently receiving systemic corticosteroids. If you experience sudden, severe pain in the abdomen, chest, or back, seek emergency medical care immediately, as these may be symptoms of aortic aneurysm or dissection, which can be life-threatening.

Abnormal heart rhythms, including life-threatening ventricular arrhythmias and QT interval prolongation (torsades de pointes), have also been reported, particularly in patients with pre-existing cardiac risk factors.

How Should You Store Ciprofloxacin Navamedic?

Quick Answer: Store at room temperature. Do not refrigerate or freeze. Keep the infusion bag in its protective foil overwrap until ready for use. The solution is light-sensitive and must be used immediately after opening. Discard any unused solution.

Proper storage of Ciprofloxacin Navamedic is essential to maintain the drug's efficacy and safety. The medication should be kept at room temperature and must not be stored in a refrigerator or freezer, as cold temperatures can affect the solution's stability and potentially cause crystallization of the active ingredient.

The infusion bags should remain in their protective foil overwrap until immediately before use, as the solution is light-sensitive. Exposure to light can degrade ciprofloxacin and reduce its potency. Once the bag is removed from the foil and opened, it should be used immediately. Any remaining solution after use must be discarded and not saved for later administration.

Always check the expiration date on the infusion bag before use. The medication should not be used after the last day of the month indicated on the packaging. Before administration, the solution should be visually inspected for any signs of deterioration, such as discoloration, cloudiness, or the presence of particles. Do not use the solution if any visible abnormalities are observed.

As with all medications, Ciprofloxacin Navamedic should be stored out of the sight and reach of children. Unused or expired medication should not be disposed of via household waste or sewage systems. Follow local regulations for proper pharmaceutical waste disposal, or return unused medication to a pharmacy for safe disposal.

What Does Ciprofloxacin Navamedic Contain?

Quick Answer: The active ingredient is ciprofloxacin (as lactate salt) at 2 mg/ml. Excipients include lactic acid, glucose monohydrate (55 mg/ml), and water for injections. Available in 100 ml and 200 ml plastic infusion bags enclosed in a protective foil overwrap.

Each milliliter of Ciprofloxacin Navamedic solution contains ciprofloxacin lactate equivalent to 2 mg of ciprofloxacin. This means a 100 ml infusion bag contains 200 mg of ciprofloxacin and a 200 ml bag contains 400 mg of ciprofloxacin.

The inactive ingredients (excipients) serve important pharmaceutical functions. Lactic acid is used to adjust and maintain the solution's pH, which is critical for ciprofloxacin's stability and solubility. The solution has a pH range of 3.5–4.6. Glucose monohydrate at a concentration of 55 mg/ml serves as a tonicity agent, ensuring the solution is compatible with intravenous administration without causing damage to blood cells. Water for injections serves as the vehicle for the solution.

Ciprofloxacin Navamedic is a clear solution, free from visible particles, packaged in plastic infusion bags. The bags are available in two sizes: 100 ml (containing 200 mg ciprofloxacin) and 200 ml (containing 400 mg ciprofloxacin). Each bag is individually wrapped in a protective foil overwrap to protect the solution from light degradation.

Compatibility and Admixture Information

For healthcare professionals: no additives should be mixed directly into the ciprofloxacin infusion solution. The solution can be administered directly or after mixing with compatible infusion solutions. If compatibility with another infusion fluid or medication has not been confirmed, the infusion must always be administered separately. Visual signs of incompatibility include precipitation, cloudiness, and discoloration. The solution is incompatible with infusion fluids or medications that are physically or chemically unstable at the solution's acidic pH (3.5–4.6), including penicillin solutions and heparin solutions, particularly when combined with alkaline-pH solutions.

References

1. European Medicines Agency (EMA). “Fluoroquinolone and quinolone antibiotics: PRAC recommends new restrictions on use.” EMA/668915/2018. Updated 2019.
2. U.S. Food and Drug Administration (FDA). “FDA Drug Safety Communication: FDA updates warnings for fluoroquinolone antibiotics on risks of mental health and low blood sugar adverse reactions.” July 2018.
3. World Health Organization (WHO). “WHO Model List of Essential Medicines – 23rd List.” Geneva: WHO; 2023.
4. British National Formulary (BNF). “Ciprofloxacin.” NICE Evidence Services. Updated 2025.
5. Patel K, Goldman JL. “Safety Concerns Surrounding Quinolone/Fluoroquinolone Therapy.” Expert Review of Anti-infective Therapy. 2020;18(3):227–233. doi:10.1080/14787210.2020.1713752
6. Zhanel GG, et al. “A critical review of the fluoroquinolones: focus on respiratory infections.” Drugs. 2002;62(1):13–59.
7. Daneman N, et al. “Fluoroquinolones and collagen associated severe adverse events: a longitudinal cohort study.” BMJ Open. 2015;5(11):e010077. doi:10.1136/bmjopen-2015-010077
8. Lee CC, et al. “Risk of aortic dissection and aortic aneurysm in patients taking oral fluoroquinolone.” JAMA Internal Medicine. 2015;175(11):1839–1847. doi:10.1001/jamainternmed.2015.5389
9. European Medicines Agency. “Ciprofloxacin – Summary of Product Characteristics (SmPC).” EMA/2019. Accessed January 2026.
10. Navamedic ASA. “Ciprofloxacin Navamedic 2 mg/ml Solution for Infusion – Summary of Product Characteristics.” Last updated January 2025.

Editorial Team